Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.

blood transfusion
platelet count
cytotoxic chemotherapy
monoclonal antibodies
hu3f8
  • 8 views
  • 13 Jun, 2022
  • 3 locations
Osteosarcoma Maintenance Therapy With OST31-164 (OST-164-01)

Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.

  • 5 views
  • 08 Jul, 2022
  • 4 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

growth factor
platelet count
graft versus host disease
brain stem tumors
cellular therapy
  • 1032 views
  • 25 Jul, 2022
  • 106 locations
Olaparib With Ceralasertib in Recurrent Osteosarcoma

This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: Olaparib Ceralasertib

growth factor
blood transfusion
MRI
kidney function tests
renal function
  • 16 views
  • 21 Oct, 2021
  • 2 locations
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.

cancer chemotherapy
myelosuppressive chemotherapy
growth factor
MRI
systemic therapy
  • 0 views
  • 10 Jul, 2022
  • 7 locations
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

(relapsed) or does not respond to treatment (refractory) or relapsed osteosarcoma. Magrolimab and dinutuximab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread

  • 0 views
  • 22 Jul, 2022
  • 7 locations
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Because there is no standard treatment at this time, patients are …

liver disease
platelet count
refractory neuroblastoma
refractory osteosarcoma
cytokines
  • 34 views
  • 10 Feb, 2022
  • 2 locations
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

This phase I trial investigates the side effects and determines the best dose of an immune cell therapy called GD2CART, as well as how well it works in treating patients with osteosarcoma or neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory). T cells are infection …

  • 0 views
  • 22 Jul, 2022
  • 1 location
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma

cancer chemotherapy
azacitidine
metastasis
metastatic disease
resectable osteosarcoma
  • 37 views
  • 05 Jun, 2022
  • 22 locations
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)

This is a Phase I clinical trial evaluating abemaciclib (LY2835219), an inhibitor of cyclin dependent-kinases 4 and 6 (Cdk 4/6) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) and in relapsed/refractory/progressive malignant brain (Grade III/IV, including DIPG; MBT) and solid tumor (ST) patients …

dexamethasone
growth factor
myelosuppressive chemotherapy
platelet count
monoclonal antibodies
  • 133 views
  • 19 Apr, 2022
  • 5 locations